PAREXEL INTERNATIONAL

Transcription

1 PAREXEL INTERNATIONAL Jefferies Healthcare Conference June 8, PAREXEL INTERNATIONAL CORP.

2 SAFE HARBOR This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding future results and events, including, without limitation, statements regarding the Company s existing capital resources and future cash flows from operations, and statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words believes, anticipates, plans, expects, intends, appears, estimates, projects, targets, and similar expressions are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. The Company s actual future results may differ materially from the results discussed in the forward-looking statements contained in this presentation. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings. including the restructuring charge announced in our press release dated June 23, 2015; the loss, modification, or delay of contracts; the Company s dependence on certain industries and clients; the Company s ability to win new business, manage growth and costs, and attract and retain employees; the Company s ability to complete additional acquisitions and to integrate newly acquired businesses including the recent acquisition of Health Advances, LLC, or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled Risk Factors of the Company s most recent Annual Report on Form 10-K and subsequent quarterly filings on form 10-Q filed with the SEC. The forward-looking statements included in this presentation represent the Company s estimates as of the date of this presentation. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company s estimates or views as of any date subsequent to the date of this presentation. This presentation includes references to non-gaap financial measures. These non-gaap measures are not prepared in accordance with generally accepted accounting principles. Pro forma information is not meant to be considered superior to or a substitute for the Company s results of operations prepared in accordance with GAAP. A reconciliation of the non-gaap financial measures to the most directly comparable GAAP measures is available on certain slides of this presentation. 2

3 PAREXEL INVESTMENT PROPOSITION Continuing to Deliver Value to our Shareholders We believe the fundamentals of the CRO market are strong PAREXEL is achieving strong new business wins and solid backlog growth from differentiated service offerings The Margin Acceleration Program has substantially improved gross margin and operating margin and is expected to generate annualized savings of $50-$60m Potential for tax rate leverage Completed $200m accelerated share buyback program, accelerating EPS growth and improving capital structure Robust growth in adjusted diluted EPS Continued strong ROIC 3

4 INDUSTRY S DEEPEST THERAPEUTIC AND CLINICAL EXPERTISE Simplifying and Speeding the Journey from Science to New Treatments 4 4

5 BUSINESS SEGMENT OVERVIEW Clinical Research Services Phase I-IV clinical development and logistics PAREXEL Consulting thought leadership in product development and commercialization PAREXEL Informatics leading eclinical solutions FY 2015 REVENUE $2 BILLION 8% 12% 80% CRS PI PC 5

6 INTEGRATED SERVICES ACROSS THE PRODUCT LIFECYCLE Phase I IV Clinical Development & Logistics Leading eclinical Solutions Product Development, Regulatory & Commercialization Consulting Phase I Phase II Phase III Phase IV Launch Development Reimbursement, Health Technology Assessment & Access 6

7 HEALTHY OUTLOOK FOR CROS $30 CRO MARKET GROWING 5%-7% 100% Outsourcing penetration rates expected to increase Market Size ($B) $25 $20 $15 $10 $5 $0 $25.3 $23.7 $22.1 $20.9 $19.1 $ % 46% 47% 48% 49% 51% E 2016E 2017E 2018E 2019E 80% 60% 40% 20% 0% Outsourcing Penetration Top CROs expected to gain share Increased complexity of trials (science, regulatory requirements, payer dynamics) favoring top global CROs Source: Jefferies & Co., July 2015 E = Estimate 7

8 CRO INDUSTRY CONSOLIDATION Large CROs are capturing more outsourcing dollars Clients want full-service capabilities Broad global presence is critical Demand for complementary or new services 8

9 OUR STRATEGY: TARGETED M&A Unlocking and Incubating Growth with Strategic Acquisitions Complementary expertise and capabilities Market adjacencies HERON April 2013 ATLAS July 2014 ClinIntel Oct QSI April 2015 Health Advances Feb Commercialization Services Consultancy Leading CRO in Turkey, the Middle East & North Africa Randomization & Trial Supply Management Pharmacovigilance Services Strategic Portfolio Planning 9

10 OUR STRATEGY: EXTEND SERVICE OFFERING PAREXEL Regulatory Outsourcing Clinical Logistics eclinical Solutions Commercialization Pharmacovigilance Modelbased Drug Development 10

11 OUR STRATEGY: eclinical INNOVATION Pre Individual Clinical Trial Applications eclinical Integration Captive Data Integration and Surveillance SMAC-based Transformation Social Media Mobile Analytics Cloud Perceptive Informatics LIQUENT Introduction of Perceptive MyTrials PAREXEL Informatics The FASTLANE Initiative PAREXEL Informatics Technology Transformation 11

12 VALUE CREATION TO DATE ADJUSTED EARNINGS PER SHARE* RETURN ON INVESTED CAPITAL (ROIC) Full Year 9 Months** $1.10 $.76 $1.69 $1.09 FY'12 FY'13 FY'14 FY'15 9M FY'16 *Adjusted numbers which exclude impact of special, restructuring or other charges as detailed on slide 21 in the Appendix to this presentation. **Represents nine months ending March 31 of the respective fiscal year Return on Invested Capital (ROIC) = Adjusted Net Income before net Interest Expense (last 12 months) / Net Operating Capital (NOC) Net Operating Capital (NOC) = Net Assets excluding Cash & Equivalents, Debt, and Tax-related assets/liabilities $2.17 $ $2.79 $ $ % 22% 20% 18% 16% 14% 12% 10% 8% 6% 4% 2% 0% 10.0% 14.9% 17.2% 21.6% 21.4% FY'12 FY'13 FY'14 FY'15 9M FY'16 WACC

13 REVENUE AND OPERATING INCOME TOTAL REVENUE ADJUSTED OPERATING INCOME* $M, AS % OF SALES 14% Dollars in Millions $1,397 $1,004 9M** $1,734 $1,271 $1,939 $1,429 $2,016 $1,493 $1,557 12% 10% 8% 6% 4% $96 $69 9M** $139 $99 $99 $200 $143 $143 $216 $160 $ $194 $194 Dollars in Millions 2% $69 FY'12 FY'13 FY'14 FY'15 9M FY'16 Source: Jefferies & Co. Report July 2015, PAREXEL estimates **Represents nine months ending March 31 of the respective fiscal year 13 PAREXEL CAGR: % CRO Market CAGR: E 6%* 13 0% FY'12 FY'13 FY'14 FY'15 9M FY'16 Adjusted EBITA Margin Adjusted Operating Margin* * See reconciliation on slide 21. **Represents nine months ending March 31 of the respective fiscal year

14 CREATING SHAREHOLDER VALUE THROUGH PROFITABLE GROWTH NEAR-TERM FOCUS FOR VALUE CREATION Drive revenue growth Expand gross margins in CRS and PI Execute Margin Acceleration Program Leverage SG&A (HR, Finance, IT) Reduce tax rate 14

15 IMPLEMENTING MARGIN ACCELERATION PROGRAM... ELEMENTS Simplifying Organizational Structure Improving Labor Mix Optimizing Global Infrastructure CONSEQUENCES Anticipated completion by year-end FY 16 Expected total charges ~ $45 million Expected FY 16 benefits/savings $20 $30 million Expected FY 17 annual pre-tax savings ~ $50 - $60 million 15

16 TARGETING OPERATING MARGIN* OF 13% TO 15% Target Margin* 13-15% Gross Margin CRS Margin Acceleration Program, Geographic footprint Gross Margin PI Leverage as business scales, Geographic footprint SG&A Leverage Efficient service functions (Finance/IT/HR) ~ bps ~ bps ~ bps Investments / FX *Adjusted Operating Margin. See reconciliation on page 21. ~ ( bps) FY15 Margin* 10.7% 16

17 RECASTING OUR TAX STRATEGY 24.8% EFFECTIVE TAX RATE* 33.7% 28.1% 28.3% 25.9% Execution believed to be on track Expect to create gradual improvement over time Necessitates collaboration with external stakeholders (clients, tax authorities) Targeted to create sustainable solution with a corporate income tax rate in the 20% - 30% range FY 12 FY 13 FY 14 FY 15 9M FY 16 * Adjusted numbers which exclude the impact of special items as detailed in the Appendix to this presentation, and posted on PAREXEL.com 17

18 OPTIMIZING OUR CAPITAL STRUCTURE FY 12 FY 16* ($M) DEPLOYED >$1.2B CAPITAL PAST 5 YEARS M&A $267 Current priority Successful acquisitions of Liquent, HERON, ATLAS, ClinIntel, Quantum Solutions India (QSI), and Health Advances Capital Expenditures $385 Invested > $300M in capital to support growth and profitability Share Buybacks ASR $200M $550 $550M in share buybacks completed, including most recent $200M ASR $0 $200 $400 $600 * Includes financials up until Q3 FY16. Includes Accelerated Share Repurchase program of $200M announced Sept

19 PAREXEL INVESTMENT PROPOSITION Continuing to Deliver Value to our Shareholders We believe the fundamentals of the CRO market are strong PAREXEL is achieving strong new business wins and solid backlog growth from differentiated service offerings The Margin Acceleration Program has substantially improved gross margin and operating margin and is expected to generate annualized savings of $50-$60m Potential for tax rate leverage Completed $200m accelerated share buyback program, accelerating EPS growth and improving capital structure Robust growth in adjusted diluted EPS Mid- to Long-term Objectives 10 % 12 % revenue growth per year (incl. M&A) 13 % 15 % adjusted operating margin 15 % 20 % growth in adjusted diluted EPS Continued strong ROIC 19

20 APPENDIX 20 20

21 GAAP TO NONGAAP RECONCILIATION 21